PCM
Penserra Capital Management Portfolio holdings
AUM
$7.17B
1-Year Return
49.58%
This Quarter Return
+7.91%
1 Year Return
+49.58%
3 Year Return
+118.16%
5 Year Return
+229.83%
10 Year Return
–
AUM
$5.51B
AUM Growth
+$99.7M
(+1.8%)
Cap. Flow
-$135M
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
18.48%
Holding
1,442
New
337
Increased
638
Reduced
343
Closed
110
Top Buys
| 1 |
Advanced Micro Devices
AMD
|
+$62.6M |
| 2 |
Pinduoduo
PDD
|
+$46.6M |
| 3 |
ThredUp
TDUP
|
+$33.9M |
| 4 |
Upwork
UPWK
|
+$30.8M |
| 5 |
LOGC
ContextLogic
LOGC
|
+$28.5M |
Top Sells
| 1 |
Revolve Group
RVLV
|
+$84.7M |
| 2 |
NetEase
NTES
|
+$53.1M |
| 3 |
QVCGA
QVC Group, Inc. Series A Common Stock
QVCGA
|
+$44.7M |
| 4 |
TripAdvisor
TRIP
|
+$41.2M |
| 5 |
Groupon
GRPN
|
+$40.8M |
Sector Composition
| 1 | Consumer Discretionary | 30.41% |
| 2 | Technology | 24.83% |
| 3 | Communication Services | 13.13% |
| 4 | Financials | 4.98% |
| 5 | Industrials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Keros Therapeutics
KROS
$628M
| $22K | ﹤0.01% |
530
+10
| +2% | +$415 |
|
1127
Morgan Stanley
MS
$243B
| $22K | ﹤0.01% |
+250
| New | +$22K |
|
1128
Rhythm Pharmaceuticals
RYTM
$6.63B
| $22K | ﹤0.01% |
1,145
+35
| +3% | +$672 |
|
1129
Scholar Rock
SRRK
$3.04B
| $22K | ﹤0.01% |
785
+20
| +3% | +$561 |
|
1130
T Rowe Price
TROW
$23.8B
| $22K | ﹤0.01% |
115
-6,590
| -98% | -$1.26M |
|
1131
Amphastar Pharmaceuticals
AMPH
$1.36B
| $21K | ﹤0.01% |
1,085
+15
| +1% | +$290 |
|
1132
AutoNation
AN
$8.57B
| $21K | ﹤0.01% |
224
+39
| +21% | +$3.66K |
|
1133
Boston Scientific
BSX
$160B
| $21K | ﹤0.01% |
+500
| New | +$21K |
|
1134
Innoviva
INVA
$1.29B
| $21K | ﹤0.01% |
1,580
-715
| -31% | -$9.5K |
|
1135
Iron Mountain
IRM
$28.6B
| $21K | ﹤0.01% |
505
-216
| -30% | -$8.98K |
|
1136
Mersana Therapeutics
MRSN
$35.1M
| $21K | ﹤0.01% |
63
| – | – |
|
1137
Omeros
OMER
$290M
| $21K | ﹤0.01% |
1,420
+30
| +2% | +$444 |
|
1138
Avidity Biosciences
RNA
$6B
| $21K | ﹤0.01% |
855
+10
| +1% | +$246 |
|
1139
Theravance Biopharma
TBPH
$701M
| $21K | ﹤0.01% |
1,485
+25
| +2% | +$354 |
|
|
GTHX
1140
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $21K | ﹤0.01% |
960
+15
| +2% | +$328 |
|
|
CCXI
1141
DELISTED
ChemoCentryx, Inc.
CCXI
| $21K | ﹤0.01% |
1,590
+25
| +2% | +$330 |
|
|
ZGNX
1142
DELISTED
Zogenix, Inc.
ZGNX
| $21K | ﹤0.01% |
1,270
+15
| +1% | +$248 |
|
1143
Arcturus Therapeutics
ARCT
$484M
| $20K | ﹤0.01% |
600
+20
| +3% | +$667 |
|
1144
American States Water
AWR
$2.83B
| $20K | ﹤0.01% |
256
+171
| +201% | +$13.4K |
|
1145
Energizer
ENR
$1.96B
| $20K | ﹤0.01% |
472
+307
| +186% | +$13K |
|
1146
Travere Therapeutics
TVTX
$1.93B
| $20K | ﹤0.01% |
1,375
+75
| +6% | +$1.09K |
|
1147
Enanta Pharmaceuticals
ENTA
$190M
| $20K | ﹤0.01% |
460
| – | – |
|
|
ITOS
1148
DELISTED
iTeos Therapeutics
ITOS
| $20K | ﹤0.01% |
800
+10
| +1% | +$250 |
|
|
JKS
1149
JinkoSolar
JKS
$1.26B
| $20K | ﹤0.01% |
+360
| New | +$20K |
|
1150
Labcorp
LH
$23B
| $20K | ﹤0.01% |
+87
| New | +$20K |
|